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Essentials
 Dabigatran etexilate may provide a new treatment
option for pediatric venous thromboembolism.
 Children aged 1 to < 12 years were given dabigatran
etexilate in an open-label, single-arm study.
 The pharmacokinetic–pharmacodynamic relationship
was similar to that seen in adult patients.
 There were no serious adverse events, bleeding events
or recurrent venous thromboembolism.
Summary. Background: The current standard-of-care
treatments for pediatric venous thromboembolism (VTE)
have limitations. Dabigatran etexilate (DE), a direct
thrombin inhibitor, may offer an alternative therapeutic
option. Objectives: To assess the pharmacokinetics, phar-
macodynamics, safety, and tolerability of a DE oral liq-
uid formulation (OLF) in pediatric patients with
VTE. Patients/Methods: Patients who had completed
planned treatment with low molecular weight heparin or
oral anticoagulants for VTE were enrolled in two age
groups (2 to < 12 years and 1 to < 2 years), and received
a DE OLF based on an age-adjusted and weight-adjusted
nomogram. Originally, patients were to receive a DE
OLF twice daily for 3 days, but the protocol was
amended to a single dose on day 1. The primary end-
points were pharmacokinetics/pharmacodynamics-related:
plasma concentrations of DE and its metabolites; acti-
vated partial thromboplastin time (APTT), ecarin clotting
time (ECT), and dilute thrombin time (dTT); and phar-
macokinetic (PK)–pharmacodynamic (PD) correlation.
Safety endpoints included incidence rates of bleeding
events and all other adverse events (AEs). Results: Eigh-
teen patients entered the study and received the DE OLF
(an exposure equivalent to a dose of 150 mg twice daily
in adults). The projected steady-state dabigatran trough
concentrations were largely comparable between pediatric
patients and adults. The PK/PD relationship was linear
for ECT and dTT, and non-linear for APTT. No serious
or severe AEs, bleeding events, or recurrent VTEs were
reported. Mild AEs were reported in three patients in the
single-dose group (screening period) and in one patient in
the multiple-dose group (on-treatment period). Conclu-
sion: The current study supports the further evaluation of
DE OLFs in pediatric patients with VTE.
Keywords: anticoagulants; dabigatran; direct thrombin
inhibitors; pediatrics; venous thromboembolism.
Introduction
The prevalence of venous thromboembolism (VTE) in
children is approximately 0.07–0.14 events per 10 000
children, and has increased in recent years [1–3]. The cur-
rent standard of care for VTE in pediatric patients is
unfractionated heparin (UFH) or low molecular weight
heparin (LMWH) followed by LMWH, or treatment with
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a vitamin K antagonist (VKA) [4–6]. However, each of
these treatment options has limitations: UFH and
LMWH require parenteral administration, and may lead
to heparin-induced thrombocytopenia and osteopenia;
and VKA has a narrow therapeutic index, requires fre-
quent International Normalized Ratio (INR) monitoring,
and is associated with multiple food and drug interactions
[4,6]. The direct thrombin inhibitor dabigatran, which is
orally administered as the prodrug dabigatran etexilate
(DE), warrants consideration as an alternative agent, as it
has been shown to be effective for the treatment of VTE
in adults, and may overcome some of the limitations
associated with current treatments [7–9].
The treatments currently recommended for children
with VTE are based on extrapolation of data obtained
from trials in adults. There are significant differences in
the etiology of VTE between adults and children, but,
once VTE has occurred, the types of treatment required
follow a similar management approach. However, there
are differences between adults and children in terms of
developmental physiology and pharmacology; therefore,
trials to evaluate the pharmacokinetics, pharmacodynam-
ics, and safety of DE in children are required [5,10].
Dabigatran is predominantly excreted via the urine
[11], so dosing according to renal function may lead to
comparable exposure between adults and pediatric
patients [12]. To date, the data on dabigatran in pediatric
plasma in vitro and in pediatric patients are similar to
those seen in adults (e.g. pharmacokinetics and the rela-
tionship between pharmacokinetics and pharmacodynam-
ics in children; and safety results in adolescent patients)
[13,14]. The planned pediatric clinical trial program for
DE has adopted a comprehensive and considered stepwise
approach to safety, in order to minimize potential expo-
sure in this vulnerable patient group. First, the safety and
tolerability of DE were confirmed in adolescents aged 12–
18 years [14], and its use was subsequently evaluated in
younger children aged 2–12 years and 1–2 years, and
finally in infants and neonates (aged 0 to < 1 year) [15].
Objective
The objective of the current study was to assess pharma-
cokinetic (PK) and pharmacodynamic (PD) data, and to
evaluate the preliminary tolerability and safety of an oral
liquid formulation (OLF) of DE in pediatric patients with
VTE aged 2 to < 12 years and 1 to < 2 years.
Methods
This was an open-label, multinational, multicenter, non-
randomized, uncontrolled, single-arm study. The target
population comprised patients (male or female) aged
between 1 year and < 12 years, with an objective diagno-
sis of VTE, who had completed planned treatment with
LMWH or the oral anticoagulant VKA for VTE. The
end of planned treatment was defined as no further need
for anticoagulant therapy. Patients should have been off
standard therapy for long enough for the INR and acti-
vated partial thromboplastin time (APTT) to be within
normal limits. Full inclusion and exclusion criteria are
shown in Table 1.
According to the initial protocol, at least eight patients
would be enrolled in each age group. However, the sample
size in the younger age group was amended to at least four
patients, in agreement with the Paediatric Committee of
the European Medicines Agency (EMA) in the European
Paediatric Investigation Plan. The sample size was not
based on a power calculation, as eight patients per age
group is generally considered to be sufficient for explora-
tory evaluations, including an assessment of whether the
observed pharmacokinetics are sufficiently described by the
model-predicted pharmacokinetics. The sample size could
have been extended if this was deemed to be necessary.
All patients in the study received the DE OLF for a mini-
mum of 5 days after and within 1 month of the last dose of
standard therapy; there was no control group. Originally,
patients were to receive weight-adjusted doses of DE twice
daily for 3 days. However, following protocol amendment,
patients were to receive a single dose on day 1. This change
was in line with EMA and US Food and Drug Administra-
tion guidance, which states that, for drugs with linear phar-
macokinetics in adults, single-dose studies in the pediatric
population often allow sufficient PK assessment [16]. Single
dosing also minimized patient exposure to study medica-
tion. Under the amended protocol, single doses were calcu-
lated by use of a nomogram based on Hayton’s formula,
which scales adult doses down according to a child’s
expected renal function, based on their weight and age [12];
age-adjusted and weight-adjusted doses were estimated to
yield an exposure equivalent to a dose of 150 mg twice daily
in adult patients. In the multiple-dose group, patients were
dosed according to a weight-based dosing method only.
A dose conversion factor of 0.646 was applied to the
calculated capsule dose to correct for dosing with the
OLF. The conversion factor was based on results from a
relative bioavailability study (NCT02171611), which
showed that a single dose of the OLF resulted in 55%
higher exposure than that obtained with capsules. There
was a 30-day follow-up. Assessments made during the
study are shown in Table S1.
The study was conducted in accordance with the Decla-
ration of Helsinki [17] and International Conference on
Harmonisation Good Clinical Practice guidelines [18], fol-
lowing approval by institutional review boards/indepen-
dent ethics committees of participating centers and the
competent authority.
Data monitoring committee
Safety and tolerability were monitored by an independent
data monitoring committee (DMC), which was composed
© 2017 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals, Inc. on behalf of International Society on Thrombosis and Haemostasis.
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of three independent members (all experts in the field of
pediatric hematology). The DMC reviewed data on an
ongoing basis after every three patients and after the last
patient in each group had completed treatment. Patients
were enrolled in two age groups: 2 to < 12 years and 1 to
< 2 years, sequentially. Recruitment to the younger group
commenced following the DMC assessment of safety data
from the older age group. On the basis of the monitored
safety data, the DMC advised on whether the trial should
continue as planned, be modified, or be discontinued.
Study endpoints
As specified in the Statistical Analysis Plan, the primary
analyses of PK/PD endpoints were limited to the single-
dose cohort; descriptive PK/PD data from the multiple-
dose cohort are reported.
PK endpoints The primary PK endpoints were the
plasma concentrations of total and free dabigatran,
unchanged DE, and the intermediate metabolites BIBR
951 BS and BIBR 1087 SE. The planned times for PK
sample collection were 1, 2, 4, 6, and 10 h postdose in the
single-dose group. To determine the similarity with adult
data, geometric mean (gMean) concentrations at 10 h
after a single dose of DE in the pediatric patients were
extrapolated to steady-state trough conditions. In order to
project the steady-state dabigatran plasma concentration,
an accumulation ratio was calculated on the basis of the
dosing interval and the assumed terminal half-life (t1/2).
PD endpoints The primary PD endpoints were central
measurements of APTT, ecarin clotting time (ECT) and
dilute thrombin time (dTT) at 2 h and 10 h after intake
of study medication. The PK–PD relationship was evalu-
ated by the use of total dabigatran concentrations and
the PD values APTT, ECT, and dTT (including the val-
ues of predose samples).
Safety endpoints Preliminary safety data for the DE
OLF were collected. The primary safety endpoints of the
study were the incidence of all bleeding events (major,
minor, and clinically relevant non-major) [19] and the
incidence of all adverse events (AEs). AEs were classified
Table 1 Inclusion and exclusion criteria
Inclusion criteria
Male or female aged 1 to < 12 years
Objective diagnosis of VTE
End of planned treatment with LMWH or the oral anticoagulant VKA for VTE. Patients should have been off standard therapy for long
enough for the INR and APTT to be within normal limits. Study medication should be given within 1 month of the last dose of standard
therapy
Written informed consent from parent or legal guardian and agreement from patient (if applicable)
Exclusion criteria
Weight < 9 kg
Conditions associated with an increased risk of bleeding:
History of hemorrhagic stroke
Major surgery within 4 weeks of visit 2 (the dosing visit)
Any planned procedure that might put the patient at an increased risk of bleeding within 5 days of taking study medication
History of intracranial, intraocular, spinal, retroperitoneal or atraumatic intra-articular bleeding
Gastrointestinal hemorrhage within the year prior to screening unless the cause has been permanently eliminated, e.g. with surgery
History of gastroduodenal ulcer disease
History of hemorrhagic disorder or bleeding diathesis
Required concurrent treatment with another LMWH, UFH, oral anticoagulant or antiplatelet agent
Fibrinolytic agents within 48 h of DE administration
Uncontrolled hypertension on antihypertensive medication (systolic and/or diastolic BP above the upper limit of normal for age and sus-
tained over 24 h)
Renal dysfunction (eGFR of < 80 mL min–1 1.73 m–2) or requirement for dialysis
Active infective endocarditis
Hepatic disease:
Active liver disease, including known hepatitis A, B, or C
Persistent ALT, AST or alkaline phosphate level of > 2 9 ULN
Women who have reached menarche with a positive pregnancy test result or who are not using a medically accepted contraceptive method
Anemia (hemoglobin level of < 80 g L1) or thrombocytopenia (platelet count of < 80 9 109 L1) at screening
Patients who have taken prohibited or restricted medication within a week of the first dose of study medication other than prior VTE
treatment
Patients who have received an investigational drug in the last 30 days prior to screening
Patients allergic/sensitive to any component of the study medication
Patients considered to be to unreliable to participate in the trial/any condition that would not allow safe participation in the trial in the
opinion of the investigator
ALT, alanine aminotransferase; APTT, activated partial thromboplastin time; AST, aspartate aminotransferase; BP, blood pressure; eGFR,
estimated glomerular filtration rate; INR, International Normalized Ratio; LMWH, low molecular weight heparin; UFH, unfractionated hep-
arin; ULN, upper limit of normal; VKA, vitamin K antagonist; VTE, venous thromboembolism.
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according to screening, on-treatment, post-treatment and
post-study periods. AEs that occurred before intake of
study medication were assigned to screening. The on-
treatment period included AEs that occurred after the
first dose until 3 days after the last treatment in the mul-
tiple-dosing group, and AEs that occurred during 48 h
after study medication in the single-dose group; the on-
treatment period also included AEs that began before
treatment but worsened in intensity during treatment.
AEs that occurred after the on-treatment period, up until
(and including) visit 3 (follow-up period, which was
scheduled 30 days [ 7 days] after intake of study medi-
cation) were assigned to the post-treatment period; the
post-study period began after visit 3.
Secondary safety endpoints were changes in laboratory
and clinical parameters, and global assessment of the tol-
erability of study medication, which was provided by the
investigator using a five-point scale (good, satisfactory,
not satisfactory, bad, or not assessable) immediately after
the patient had taken the study medication. As part of
the global assessment of tolerability, patients who were
old enough were asked to assess the taste of the study
medication (very good, good, satisfactory, bad, or very
bad) and describe the taste itself (bitter, sweet, salty, sour,
or other). Other endpoints included the occurrence of
clinical outcomes, including recurrent thrombosis, post-
thrombotic syndrome, pulmonary embolism, and total
and VTE-related mortality.
Bioanalytic methods
Concentrations of total dabigatran, free dabigatran, DE,
and intermediate metabolites were analyzed with vali-
dated HPLC–tandem mass spectrometry methods at
Nuvisan GmbH, Neu-Ulm, Germany [14]. Analysis of
APTT, ECT and dTT was performed at Menal GmbH,
Emmendingen, Germany. Clotting times were determined
with an MC 10 PLUS coagulometer (ABW Medizin und
Technik, Lemgo, Germany) [14]. The coefficient of varia-
tion (CV), which is a measure of assay imprecision, was
≤ 6.1% for all coagulation parameters.
Samples were thawed at  37 °C in a waterbath, cen-
trifuged for 3 min at 1000 9 g, and mixed well before the
coagulation assays were performed.
dTT The plasma sample was diluted 1 : 8 with 0.9%
isotonic sodium chloride solution. Fifty microliters of the
diluted study sample and then 100 lL of R1 (normal
pooled plasma) were pipetted into a cuvette, and the mix-
ture was incubated for 2 min at 37°C, before 100 lL of
R2 (human calcium thrombin) was added; the time lag
between the addition of R2 and clot formation deter-
mined the dTT.
APTT Fifty microliters of study sample and 50 lL of
kaolin/cephalin reagent were pipetted into a cuvette, and
incubated for 3 min at 37 °C, after which 50 lL of
0.025 M CaCl2 was added; the time lag between the addi-
tion of CaCl2 and clot formation determined the APTT.
ECT Seventy-five microliters of study sample and then
75 lL of imidazole/veronal buffer (one part imidazole
buffer plus 0.77 parts veronal buffer) were pipetted into a
cuvette. The mixture was incubated for 2 min at 37 °C,
and then 75 lL of ecarin (6 IU mL1) was added; the
time lag between the addition of ecarin and clot forma-
tion determined the ECT.
Data analysis
Descriptive statistical methods were applied to safety,
PK, PD and clinical endpoints. For PK endpoints, the
maximum concentration (Cmax), time from dosing to the
maximum concentration (tmax) and area under the con-
centration–time curve from time interval 0 up to the last
quantifiable data point (AUC0–tz) were calculated and
presented as gMean and geometric CV (gCV), or median
and range. A linear regression model and a non-linear
maximum effect model were used for analysis of the PK–
PD relationship. The safety analysis was based on all
patients who received at least one dose of the DE OLF.
The PK, PD and PK/PD analysis included all treated
patients who provided at least one PK/PD observation
and had no relevant protocol violations.
Results
A total of 20 pediatric patients were enrolled (Fig. 1).
However, one patient did not have an objective diagnosis
at screening, and a second patient had hepatic disease
reported at visit 2. Therefore, 18 patients entered the
study, which was conducted at seven active centers in six
countries. All participants completed the planned obser-
vation time; there were no discontinuations. Three
patients received multiple doses of the DE OLF (twice
daily for 3 days). Six patients aged 1 to < 2 years and
nine patients aged 2 to < 12 years were treated with a sin-
gle dose of the DE OLF.
There were more male than female patients (61% ver-
sus 39%). The mean ages were 17.3 months (standard
deviation [SD] 4.0 months) in the group aged 1 to
< 2 years, and 5.2 years (SD 2.6 years) in the single-dose
group aged 2 to < 12 years. Additional baseline charac-
teristics are shown in Table 2; those for the three patients
who received multiple doses before the protocol was
amended are shown in Table S2. All 18 patients were
included in the treated and PK sets.
PK results
Patients aged 1 to < 2 years In the single-dose group of
patients aged 1 to < 2 years, the results for total
© 2017 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals, Inc. on behalf of International Society on Thrombosis and Haemostasis.
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dabigatran plasma concentration were as follows: gMean
Cmax, 129 ng mL
1; concentration 10 h postdose (C10),
34.8 ng mL1; and AUC0–tz, 715 ng mL
1 h1. The gCVs
were 9.84%, 41.4%, and 22.5%, respectively (Table 3;
Fig. 2). Free dabigatran concentrations were approxi-
mately 10–15% lower than total dabigatran concentra-
tions (Table S3).
Patients aged 2 to < 12 years In the single-dose group
of patients aged 2 to < 12 years, gMean Cmax, C10 and
AUC0–tz were 116 ng mL
1, 28.2 ng mL1, and
658 ng mL1 h1, respectively, for total dabigatran
plasma concentration, with gCVs of 38.6%, 37%, and
32.5% (Table 3; Fig. 2). Free dabigatran PK parameters
are shown in Table S3. The projected steady-state dabiga-
tran trough concentrations in the current study were lar-
gely comparable to those seen in adult patients in the
RE-COVER trial; that is, they fell between the first and
third quartiles of the adult RE-COVER concentrations
(Table 4) [7].
PK results for the three patients who received multiple
doses of the DE OLF are shown in Table S4.
In all treated patients, plasma concentrations of
unchanged dabigatran and the intermediate metabolites
were low or undetectable.
PD results
For both single-dosing age groups, the mean coagulation
times for APTT, dTT and ECT were prolonged at 2 h
postdose and then fell towards baseline values at 10 h
(Table 5). Owing to a very limited amount of evaluable
data from the multiple-dose group, PD data were not
included in the PD analysis.
PK–PD relationship
For the single-dose group, linear PK–PD relationships
were observed for dTT and ECT, as shown by R values
close to 1 and slope parameters that were significantly dif-
ferent from zero (Fig. 3B, C). For ECT (1 to < 2 years),
ECT (2 to < 12 years), dTT (1 to < 2 years), and dTT (2
to < 12 years), slope and R2 estimates, respectively, were:
0.322 s mL ng–1 (standard error [SE] 0.015 s mL ng–1)
with R2 = 0.970; 0.298 s mL ng–1 (SE 0.039 s mL ng–1)
with R2 = 0.764; 0.113 s mL ng–1 (SE 0.008 s mL ng–1) with
R2 = 0.919; and 0.164 s mL ng–1 (SE 0.013 s mL ng–1)
with R2 = 0.859. As the PK–PD relationship for APTT
is known to be non-linear in adults, non-linear regres-
sion lines were fitted to the concentration–APTT data
(Fig. 3A). Other than the baseline parameter,
Screened
Eligible patients
•
•
Single-dose dabigatran etexilate, N = 15 Multiple-dose dabigatran etexilate, N = 3
(3 days, twice daily)1 to < 2 years, n = 6
2 to < 12 years, n = 9
age-adjusted and weight-adjusted dose
All received the planned
Seven received the planned dose
Two received less than the planned dose,
but more than the minimum required dose
Two received the planned weight-adjusted
doses* with minor deviations in volume
One received a higher volume for all six doses
Evaluable, N = 15
*80% of the target dose on dose 1, followed by 100% for all subsequent five doses
Evaluable, N = 3
Lost to follow-up, n = 0
Discontinued treatment, n = 0
Lost to follow-up, n = 0
Discontinued treatment, n = 0
N = 20
N = 18
Excluded
No objective diagnosis (n = 1)
Hepatic disease reported (n = 1)
Fig. 1. Patient flow through the study.
© 2017 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals, Inc. on behalf of International Society on Thrombosis and Haemostasis.
Dabigatran for venous thromboembolism in children 2151
parameter estimates were not significantly different
from zero. Age did not appear to affect the PK–PD rela-
tionship when analyzed by linear regression with age as a
covariate.
Preliminary safety results
AEs during screening were reported in three patients
(17%), all in the single-dose groups: one patient in the
group aged 1 to < 2 years had mild respiratory tract
infection, one patient aged 2 years had nasopharyngitis
and ear pain, both of which were mild in intensity, and
one patient aged 7 years had mild back pain. All three
patients recovered. One patient (6%) aged 6 years in the
multiple-dose group experienced leukopenia and dizziness
during the on-treatment period. The patient recovered
from both of these AEs, which were mild and considered
to be unrelated to the study drug. T
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Table 2 Baseline characteristics of patients in the single-dose groups
Single dose
1 to < 2 years 2 to < 12 years
Treated patients, N (%) 6 (100) 9 (100)
Female, n (%) 2 (33) 3 (33)
Race, n (%)
White 5 (83) 6 (67)
Asian 1 (17) 3 (33)
Age (years), mean (SD) 1.4 (0.3) 5.2 (2.6)
Minimum 1 2
Maximum 2 8
Height (cm), mean (SD) 80.0 (6.8) 110.9 (17.3)
Weight (kg), mean (SD) 10.68 (2.27) 22.56 (11.00)
BMI (kg m2), mean (SD) 16.55 (1.59) 17.27 (3.07)
eGFR (mL min–1 1.73 m–2),
mean (SD)
120.91 (18.37) 127.91 (29.21)
Body surface area (m2),
mean (SD)
0.472 (0.070) 0.814 (0.254)
VTE subtype (qualifying event), n (%)*
Pulmonary embolism 0 1 (11)
Vena cava thrombosis 1 (17) 2 (22)
Upper extremity thrombosis 2 (33) 3 (33)
Lower extremity thrombosis 2 (33) 1 (11)
Sinus venous thrombosis 0 5 (56)
Central venous line-related
thrombosis
2 (33) 2 (22)
Not specified/recorded 2 (33) 0
Anticoagulant used prior to study drug, n (%)*
UFH 1 (17) 1 (11)
LMWH 2 (33) 7 (78)
VKA 0 3 (33)
Data not available 4 (67) 1 (11)
BMI, body mass index; eGFR, estimated glomerular filtration rate;
LMWH, low molecular weight heparin; SD, standard deviation;
UFH, unfractionated heparin; VKA, vitamin K antagonist; VTE,
venous thromboembolism. All demographic information was
recorded at visit 1 (screening), except for age (years), which was
based on the time of the study drug intake. *Patients could have
more than one type of VTE or be receiving more than one anticoag-
ulant prior to the study drug.
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No AEs occurred during the post-treatment or post-
study periods, and there were no deaths, AEs leading to
discontinuation, or serious, severe or drug-related AEs.
There were no reports of bleeding events, recurrent VTE
or post-thrombotic syndrome, and there were no clinically
significant findings from laboratory analyses as compared
with baseline.
Tolerability was ‘good’ in six patients (33%), ‘satisfac-
tory’ in three (17%), ‘not satisfactory’ in six (33%), ‘bad’
in two (11%), and not assessable in one (6%). Taste,
which was assessed only in the age groups aged 2 to
< 12 years, was reported as ‘satisfactory’ by five patients
(28%), ‘bad’ by two (11%), and ‘very bad’ by three
(17%); no patient reported taste as ‘good’ or ‘very good’.
Data were missing for eight patients (44%). In addition,
taste was described as ‘bitter’ by five patients (28%) and
‘sour’ by four (22%); no patients considered taste to be
‘sweet or salty’, one patient (6%) selected none of the
above, and data were missing for eight patients (44%).
Discussion
The current study assessed the pharmacokinetics, pharma-
codynamics, safety, and tolerability of the DE OLF in
pediatric patients aged 1 to < 12 years, which is necessary
to determine whether the results reflect those observed in
the adult population. Projected steady-state dabigatran
trough concentrations in the current study were largely
comparable to those seen in adults with VTE. Projections
were necessary, as steady-state concentrations (in adults)
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cannot be compared with single-dose conditions. To pro-
ject the steady-state dabigatran plasma concentration,
gMean concentrations at 10 h after dosing were extrapo-
lated by use of an accumulation ratio based on t1/2 and
the dosing interval (for a twice-daily dosing regimen). As
plasma samples were only collected up to 10 h postdose,
an exact estimation of the true t1/2 of dabigatran in chil-
dren was not possible (a sampling time of 48 h is typically
required for a reliable estimation of dabigatran half-life,
which was not feasible in this pediatric population). On
the basis of the plasma samples taken at 10 h postdose
and data from younger adults, the t1/2 of dabigatran in
pediatric patients was assumed to be 5–10 h; estimation
of the t1/2 is a potential limitation associated with the
projections.
In the current study, a dose conversion factor was used
to correct for dosing with the OLF based on results from
a relative bioavailability study (NCT02171611). However,
the findings from a larger relative bioavailability trial
(NCT02044367) using multiple doses subsequently
showed a much smaller difference in exposure between
the two formulations, so a conversion factor was not nec-
essary. If no conversion factor had been applied in the
current study, the gMean C10 value of total dabigatran
would have been higher in both pediatric age groups (the
gMean C10 value shown in Table 3 was divided by 0.646
before extrapolation to the steady-state trough concentra-
tion, as described in the footnote of Table 4). No conver-
sion factor will be applied to dosing nomograms in future
pediatric studies.
Table 5 Pharmacodynamic results for a single dose, for patients aged 1 to < 2 years and 2 to < 12 years
APTT dTT ECT
N Mean CV (%) N Mean CV (%) N Mean CV (%)
Single-dose patients aged 1 to < 2 years
Ebase (s) 6 32.3 24.6 6 31.9 4.67 6 36.9 7.49
E2 (s) 6 47.5 24.7 6 46.6 6.02 6 79.8 5.15
E10 (s) 5 40.3 19.6 6 35.5 6.02 5 49.7 5.36
ER2 (ratio) 6 1.51 20.5 6 1.46 4.27 6 2.17 11
ER10 (ratio) 5 1.27 12.5 6 1.11 4.1 5 1.33 7.56
Single-dose patients aged 2 to < 12 years
Ebase (s) 7 34.9 24.5 9 35.6 10.1 6 36.8 10.5
E2 (s) 9 77 54.6 9 53.6 18.4 7 73.6 22.1
E10 (s) 8 58.4 40.6 9 39.7 9.76 7 52.2 10.3
ER2 (ratio) 7 2.48 53.1 9 1.51 18.5 5 2.04 32.6
ER10 (ratio) 6 2.1 59.4 9 1.12 9.43 5 1.44 14.1
APTT, activated partial thromboplastin time; CV, coefficient of variation; dTT, dilute thrombin time; E2, effect 2 h postdose; E10, effect at
10 h postdose; Ebase, baseline effect; ECT, ecarin clotting time.
Table 4 Projected steady-state total dabigatran trough concentrations in patients aged 1 to < 2 years and patients aged 2 to < 12 years as com-
pared with total dabigatran trough concentrations in adults in RE-COVER
Current study in pediatric patients (single-dose groups only)
RE-COVER (adults)*
Total dabigatran concentration 10 h
postdose (ng mL1)
Projected steady-state total dabigatran
trough concentration (ng mL1)
Total dabigatran trough
concentration (ng mL1)1 to < 2 years 2 to < 12 years 1 to < 2 years 2 to < 12 years
N 6 9 6 9 850
gMean 34.8(a) 28.2(b) 53.1–87.6(c) 40.8–67.3(d) 59.7
gCV (%) 41.4 37.0 – – 81.6
Median 30.2 28.8 – – 58.7
CV (%) 41.7 35.4 – – 79.7
Q1 – – – – 38.6
Q3 – – – – 94.5
P10 26.3
P90 146
CV, coefficient of variation; gCV, geometric coefficient of variation; gMean, geometric mean; P10, 10th percentile; P90, 90th percentile; Q1,
first quartile; Q3, third quartile. Projected steady-state trough (d) or (c) = (C10 [b] or [a])/BA factor 9 AR 9 2-h decay rate. BA is bioavail-
ability (dose conversion) factor (0.646), and AR is accumulation ratio, i.e. 1/(1 – eks), where k = 0.693/t1/2, s = 12 h, and t1/2 = 5–10 h. The
2-h decay rate = ekt; where k = t1/2/0.693, t = 2 h, and t1/2 = 5–10 h. *At day 30.
© 2017 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals, Inc. on behalf of International Society on Thrombosis and Haemostasis.
2154 J. M. L. Halton et al
180A
B
C
1 to < 2 years
2 to < 12 years
1 to < 2 years R 2 = 0.919
R 2 = 0.8592 to < 12 years
1 to < 2 years R 2 = 0.970
R 2 = 0.7642 to < 12 years
150
120
AP
TT
 v
al
ue
s 
(s)
90
60
30
0
100
80
dT
T 
va
lu
es
 (s
)
60
40
20
0
100
80
EC
T 
va
lu
es
 (s
)
60
40
20
0
150125100755025
Total dabigatran plasma concentration (ng mL–1)
0
150125100755025
Total dabigatran plasma concentration (ng mL–1)
0
150125100755025
Total dabigatran plasma concentration (ng mL–1)
0
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The results of the current study show that there was a
linear PK–PD relationship for dTT and ECT, similar to
that seen in adults and adolescents with VTE. The PK–
PD relationship for APTT was non-linear, as observed in
the adult population.
The results of the taste assessment were mixed, with
11% and 17% of patients rating the taste as ‘bad’ or
‘very bad’, respectively. However, the tolerability and pre-
liminary safety profiles were otherwise favorable. In addi-
tion to the OLF, a pellet formulation of DE is under
development, and this will also be subject to acceptability
and taste assessments. Currently, no specific pediatric for-
mulations of antithrombotic drugs are available, but they
are under development. Therefore, a palatable pediatric
formulation such as the OLF or a pellet formulation
would provide a much needed alternative for children
who have difficulties with injections or swallowing cap-
sules.
The study has certain limitations, including the reliance
on projected steady-state dabigatran concentrations.
Another limitation is the population size, which is small
relative to the broad age range of the eligible population
from a safety perspective. However, for a PK analysis,
which is the focus of the study, the sample size was con-
sidered to be sufficient. There was a lack of evaluable
data from the multiple-dose group (only three patients).
In addition, the three patients in the multiple-dose group
were dosed according to a weight-based nomogram,
which was replaced with an age-based and weight-based
nomogram in the single-dose groups and in subsequent
pediatric studies. Given the limited study power, the
safety confidence limits are too wide to conclude that
dabigatran is safe in children. Indeed, the safety and effi-
cacy of DE in pediatric patients are currently being evalu-
ated in additional clinical studies.
In summary, the results of the current study support
further evaluation of DE in pediatric patients with VTE,
and provide support for the dosing regimen in the ongo-
ing phase IIb/III studies. DE may provide a new treat-
ment option in this patient population, overcoming the
limitations associated with current treatments.
Addendum
J. M. L. Halton was the coordinating investigator of the
trial, and was involved in concept design, analysis, inter-
pretation of data, writing and reviewing the draft manu-
script, and approval of the final version to be published.
M. Albisetti is a member of a Pediatric Expert Working
Group for Boehringer Ingelheim. B. Biss Trial Clinical
Monitor. L. Bomgaars is a member of a Pediatric Expert
Working Group for Boehringer Ingelheim. M. Brueck-
mann contributed to the trial design, study protocol, and
trial conduct. S. Gropper contributed to the trial design,
study protocol, and trial conduct. R. Harper contributed
to the trial design, study protocol, and trial conduct.
F. Huang contributed to the trial design, study protocol,
data analysis, and study report writing. M. Luciani is
a member of a Pediatric Expert Working Group for
Boehringer Ingelheim. H. Maas contributed to the trial
design and study protocol. I. Tartakovsky contributed to
the trial design, study protocol, and trial conduct. L. G.
Mitchell was the coordinating investigator of the trial. All
authors provided input and critical review of the manu-
script, and approved the final manuscript.
Acknowledgements
This study was funded by Boehringer Ingelheim Pharma
GmbH & Co. KG. Medical writing assistance, supported
financially by Boehringer Ingelheim Pharma GmbH &
Co. KG, was provided by D. Sherwood of PAREXEL.
Disclosure of Conflict of Interests
J. M. L. Halton, M. Albisetti, M. Luciani, and L. Bom-
gaars are members of a Pediatric Expert Working Group
for Boehringer Ingelheim. B. Biss, M. Brueckmann, S.
Gropper, R. Harper, F. Huang, H. Maas, and I. Tar-
takovsky are employees of Boehringer Ingelheim. L. G.
Mitchell is a consultant for Boehringer Ingelheim, Pfizer,
and Bristol-Myers Squibb.
Supporting Information
Additional Supporting Information may be found in the
online version of this article:
Table S1. Assessments made during the study.
Table S2. Baseline characteristics of patients in the multi-
ple-dose group.
Table S3. Free dabigatran plasma concentrations in sin-
gle-dose groups.
Table S4. Total dabigatran concentration in the multiple-
dose group in patients aged 2 to < 12 years (too few
evaluable assessments for summary statistics).
References
1 Andrew M, David M, Adams M, Ali K, Anderson R, Barnard
D, Bernstein M, Brisson L, Cairney B, DeSai D. Venous throm-
boembolic complications (VTE) in children: first analyses of the
Canadian Registry of VTE. Blood 1994; 83: 1251–7.
2 van Ommen CH, Heijboer H, Buller HR, Hirasing RA, Heij-
mans HS, Peters M. Venous thromboembolism in childhood: a
prospective two-year registry in The Netherlands. J Pediatr 2001;
139: 676–81.
3 Raffini L, Huang YS, Witmer C, Feudtner C. Dramatic increase
in venous thromboembolism in children’s hospitals in the United
States from 2001 to 2007. Pediatrics 2009; 124: 1001–8.
4 Parasuraman S, Goldhaber SZ. Venous thromboembolism in
children. Circulation 2006; 113: e12–16.
5 Bonduel MM. Oral anticoagulation therapy in children. Thromb
Res 2006; 118: 85–94.
© 2017 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals, Inc. on behalf of International Society on Thrombosis and Haemostasis.
2156 J. M. L. Halton et al
6 Monagle P, Chan AK, Goldenberg NA, Ichord RN, Journey-
cake JM, Nowak-Gottl U, Vesely SK. Antithrombotic therapy in
neonates and children: Antithrombotic Therapy and Prevention
of Thrombosis, 9th ed: American College of Chest Physicians
Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:
e737S–801S.
7 Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S,
Eriksson H, Baanstra D, Schnee J, Goldhaber SZ. Dabigatran
versus warfarin in the treatment of acute venous thromboem-
bolism. N Engl J Med 2009; 361: 2342–52.
8 Schulman S, Kearon C, Kakkar AK, Schellong S, Eriksson H,
Baanstra D, Kvamme AM, Friedman J, Mismetti P, Goldhaber
SZ. Extended use of dabigatran, warfarin, or placebo in venous
thromboembolism. N Engl J Med 2013; 368: 709–18.
9 Schulman S, Kakkar AK, Goldhaber SZ, Schellong S, Eriksson
H, Mismetti P, Christiansen AV, Friedman J, Le MF, Peter N,
Kearon C. Treatment of acute venous thromboembolism with
dabigatran or warfarin and pooled analysis. Circulation 2014;
129: 764–72.
10 Kuhle S, Male C, Mitchell L. Developmental hemostasis: pro-
and anticoagulant systems during childhood. Semin Thromb
Hemost 2003; 29: 329–38.
11 Stangier J, Stahle H, Rathgen K, Roth W, Shakeri-Nejad K.
Pharmacokinetics and pharmacodynamics of dabigatran etexi-
late, an oral direct thrombin inhibitor, are not affected by
moderate hepatic impairment. J Clin Pharmacol 2008; 48:
1411–19.
12 Hayton WL. Maturation and growth of renal function: dosing
renally cleared drugs in children. AAPS PharmSci 2000; 2: 22–28.
13 Dietrich K, Stang L, Van Ryn J, Mitchell LG. Assessing the
anticoagulant effect of dabigatran in children: an in vitro study.
Thromb Res 2015; 135: 630–5.
14 Halton JM, Lehr T, Cronin L, Lobmeyer MT, Haertter S, Bel-
letrutti M, Mitchell LG. Safety, tolerability and clinical pharma-
cology of dabigatran etexilate in adolescents. An open-label
phase IIa study. Thromb Haemost 2016; 116: 461–71.
15 Halton JML, Picard AC, Harper R, Huang F, Brueckmann M,
Gropper S, Maas H, Tartakovsky I, Nurmeev I, Mitchell L,
Brandao LR, Albisetti M. Pharmacokinetics (PK) and pharma-
codynamics (PD), safety and tolerability of a single-dose oral
solution of dabigatran etexilate given after standard anticoagu-
lant therapy in children from birth to less than one year old,
with venous thromboembolism. Blood 2016; 128: 1441.
16 ICH Topic E11 Clinical Investigation of Medicinal Products in
the Paediatric Population. http://www.ich.org/fileadmin/Public_
Web_Site/ICH_Products/Guidelines/Efficacy/E11/Step4/E11_Guide
line.pdf. Accessed 25 July 2016.
17 World Medical Association Declaration of Helsinki. Ethical prin-
ciples for medical research involving human subjects. JAMA
2013; 310: 2191–4.
18 ICH Harmonised Tripartite Guideline. Guideline for Good Clini-
cal Practice E6. http://www.ich.org/fileadmin/Public_Web_Site/
ICH_Products/Guidelines/Efficacy/E6/E6_R1_Guideline.pdf.
Accessed 25 July 2016.
19 Mitchell LG, Goldenberg NA, Male C, Kenet G, Monagle P,
Nowak-Gottl U. Definition of clinical efficacy and safety out-
comes for clinical trials in deep venous thrombosis and pulmonary
embolism in children. J Thromb Haemost 2011; 9: 1856–8.
© 2017 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals, Inc. on behalf of International Society on Thrombosis and Haemostasis.
Dabigatran for venous thromboembolism in children 2157
